Loading stock data…
AEON
$0.83-0.05 (-5.68%)
Market OpenUpdated 12:36 PM EDT
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AEON Biopharma, Inc. in the Healthcare sector is trading at $0.83. Wall Street consensus targets $6.70 (2 analysts), implying a +707.2% move over the next 12 months. The stock is currently 43% below its 52-week high of $1.45, remaining 12.6% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +707.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 20) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$0.83
Potential Downside
0%
Whystock Fair Value$0.83
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$27.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.73
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
71.28%
Volume
Today's trading volume
91,472
Recent News
Aeon Biopharma announces FDA feedback after Type 2a meeting
Aeon Biopharma (AEON) announced feedback from the FDA following a biosimilar biological product development Type 2a meeting. During the meeting, held in January, the FDA reviewed the company’s proposed analytical similarity strategy under the 351(k) biosimilar pathway and provided feedback supporting the company’s planned analytical development approach. The agency acknowledged the scientific challenges associated with characterizing a 900 kDa botulinum neurotoxin complex, provided constructive
An Intrinsic Calculation For Aeon Co. (M) Bhd. (KLSE:AEON) Suggests It's 42% Undervalued
Key Insights Aeon (M) Bhd's estimated fair value is RM1.89 based on 2 Stage Free Cash Flow to Equity Aeon (M) Bhd's...
Investors in Aeon (M) Bhd (KLSE:AEON) have unfortunately lost 24% over the last year
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
The Returns At Aeon (M) Bhd (KLSE:AEON) Aren't Growing
What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Aeon Co. (M) Bhd.'s (KLSE:AEON) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
With its stock down 7.9% over the past three months, it is easy to disregard Aeon (M) Bhd (KLSE:AEON). However, the...